节点文献

替卡西林/克拉维酸和头孢他啶治疗中重度感染41例

Treatment of moderate and severe infection with ticarcillin/clavulanic acid versus ceftazidime in 41 patients

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 杜斌; 刘大为; 隆云; 许媛; 安友仲; 尹培刚; 骆辛;

【Author】 DU Bin 1,LIU Da wei 1,LONG Yun 1,XU Yuan 2,AN You zhong 3,YIN Pei gang 4,LUO Xin 5 (1? Department of Critical Care Medicine,Peking Union Medical College Hospital,Beijing 100730, China ;2? Surgical Intensive Care Unit,Beijing Tongren Hospital,Beijing 100730, China ; 3? Surgical Intensive Care Unit,People’s Hospital,Peking University,Beijing 100044, China ;4? Department of Critical Care Medicine,Sino Japan Friendship Hospital,Beijing 100029, China ;5? Department of Critical Care Medicine,Beijing Fuxing Hospital,Beijing 100038, China )

【机构】 中国医学科学院中国协和医科大学北京协和医院ICU; 北京同仁医院外科ICU; 北京大学人民医院外科ICU; 中日友好医院ICU; 北京复兴医院ICU 北京100730; 北京100730; 北京100044; 北京100029; 北京100038;

【摘要】 目的 :比较替卡西林 克拉维酸和头孢他啶治疗中重度感染的疗效及安全性。方法 :采用前瞻性随机、开放、对照试验 ,治疗组 2 1例用替卡西林 克拉维酸 3.2g ,q8h ,iv ;对照组 2 0例 ,用头孢他啶 1g ,q8h ,iv ,2组疗程为 3~ 14d。结果 :治疗组和对照组临床治疗总有效率分别为 76 % (16 2 1)和 6 5 % (13 2 0 ) ,无统计学差异 (P >0 .0 5 ) ;细菌学清除率分别为 71% (15 2 1)和 5 5 % (11 2 0 ) ;不良反应发生率分别为 14 % (3 2 1)和 5 % (1 2 0 )。结论 :替卡西林 克拉维酸治疗中重度感染时疗效和不良反应与头孢他啶相似。

【Abstract】 Objective:To compare the clinical efficacy and safety profile of ticarcillin/clavulanic acid and ceftazidime in treatment of moderate and severe infection.Methods:A total of 41 patients were enrolled in this prospective,randomized,open,controlled study.They were divided into two groups,the test group( n =21) received ticarcillin/clavulanic acid (3.2g,q8h,iv) and the control group( n =20) recieved ceftazidime(1g,q8h,iv) for 3~14 days.Results:The clinical response rates,bacteriologic eradication rates,and adverse reaction rates were similar in the test group (76%,71% and 14%,respectively) and the control group (65%, 55% and 5%, respectively).Conclusion:Ticarcillin/clavulanic acid and ceftazidime were of equivalent clinical efficacy and safety in treatment of moderate and severe infection.

  • 【文献出处】 中国新药杂志 ,Chinese New Drugs Journal , 编辑部邮箱 ,2002年08期
  • 【分类号】R453
  • 【被引频次】3
  • 【下载频次】171
节点文献中: 

本文链接的文献网络图示:

本文的引文网络